Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

406 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans.
Parasrampuria DA, Schoedel KA, Schuller R, Gu J, Ciccone P, Silber SA, Sellers EM. Parasrampuria DA, et al. Among authors: sellers em. J Clin Pharmacol. 2007 Dec;47(12):1476-88. doi: 10.1177/0091270007308615. Epub 2007 Oct 25. J Clin Pharmacol. 2007. PMID: 17962423 Clinical Trial.
Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist: a randomized, double-blind, placebo- and active-controlled, crossover study in recreational polydrug users.
Schoedel KA, Addy C, Chakraborty B, Rosko K, Dunbar S, Maes A, Chen N, Stoch SA, Wagner J, Chodakewitz J, Sellers EM. Schoedel KA, et al. Among authors: sellers em. J Clin Psychopharmacol. 2012 Aug;32(4):492-502. doi: 10.1097/JCP.0b013e31825d380d. J Clin Psychopharmacol. 2012. PMID: 22722508 Clinical Trial.
A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use.
Schoedel KA, Chen N, Hilliard A, White L, Stott C, Russo E, Wright S, Guy G, Romach MK, Sellers EM. Schoedel KA, et al. Among authors: sellers em. Hum Psychopharmacol. 2011 Apr;26(3):224-36. doi: 10.1002/hup.1196. Hum Psychopharmacol. 2011. PMID: 21671456 Clinical Trial.
Human abuse liability evaluation of CNS stimulant drugs.
Romach MK, Schoedel KA, Sellers EM. Romach MK, et al. Among authors: sellers em. Neuropharmacology. 2014 Dec;87:81-90. doi: 10.1016/j.neuropharm.2014.04.014. Epub 2014 Apr 30. Neuropharmacology. 2014. PMID: 24793872 Review.
Assessment of Pharmacokinetic and Pharmacodynamic Interactions Between Albumin-Fused Mutated Butyrylcholinesterase and Intravenously Administered Cocaine in Recreational Cocaine Users.
Shram MJ, Cohen-Barak O, Chakraborty B, Bassan M, Schoedel KA, Hallak H, Eyal E, Weiss S, Gilgun-Serki Y, Sellers EM, Faulknor J, Spiegelstein O. Shram MJ, et al. Among authors: sellers em. J Clin Psychopharmacol. 2015 Aug;35(4):396-405. doi: 10.1097/JCP.0000000000000347. J Clin Psychopharmacol. 2015. PMID: 26082975 Clinical Trial.
Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study.
Schoedel KA, Sun H, Sellers EM, Faulknor J, Levy-Cooperman N, Li X, Kennedy WP, Cha JH, Lewis NM, Liu W, Bondiskey P, McCrea JB, Panebianco DL, Troyer MD, Wagner JA. Schoedel KA, et al. Among authors: sellers em. J Clin Psychopharmacol. 2016 Aug;36(4):314-23. doi: 10.1097/JCP.0000000000000516. J Clin Psychopharmacol. 2016. PMID: 27253658 Clinical Trial.
406 results